NICE

June 14, 2018

Zytiga Rejected in England as First-line Treatment for Newly Diagnosed Advanced Prostate Cancer

News

Janssen’s medication Zytiga (abiraterone) was recently rejected as a first-line treatment for newly diagnosed advanced prostate cancer on the National Health Service (NHS) in England following an initial draft recommendation from the National ... Read more

September 1, 2017September 1, 2017

NICE Approves SpaceOAR Hydrogel Use in UK

News

The National Institute for Health and Care Excellence (NICE) in the U.K. has issued a guidance for prostate cancer care that supports the use of SpaceOAR hydrogel as a protective barrier to reduce the ... Read more

December 14, 2015December 14, 2015

NICE Issues Draft Guidance on Astellas’ Xtandi and Janssen’s Zytiga for Prostate Cancer Treatment

News

NICE issued its final draft guidance recommending enzalutamide (Xtandi, by Astellas Pharma) for prostate cancer (PC) patients who have already tried first-line treatments with no success, for those who have none ... Read more